Russell Investments Group
TVRD

Russell Investments Group’s Tvardi Therapeutics TVRD Stock Holding History

Russell Investments Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.1K Buy
43,228
+19,921
+85% +$62.5K ﹤0.01% 3504
2026
Q1 		$74.1K Buy
23,307
+7,341
+46% +$28.8K ﹤0.01% 3179
2025
Q4 		$68.7K Buy
15,966
+14,866
+1,351% +$133K ﹤0.01% 3183
2025
Q3 		$42.9K Buy
+1,100
New +$31.3K ﹤0.01% 3350
2024
Q3 		– Sell
-365
Closed -$3.39K – 3821
2024
Q2 		$3.39K Buy
+365
New +$8.71K ﹤0.01% 3288
2024
Q1 		– Sell
-876
Closed -$23.4K – 3378
2023
Q4 		$23.4K Sell
876
-7,285
-89% -$302K ﹤0.01% 2727
2023
Q3 		$494K Buy
8,161
+7,215
+763% +$677K ﹤0.01% 2230
2023
Q2 		$96.3K Buy
946
+910
+2,528% +$125K ﹤0.01% 2610
2023
Q1 		$6.37K Buy
+36
New +$12.1K ﹤0.01% 2929
2022
Q2 		– Sell
-915
Closed -$398K – 2980
2022
Q1 		$398K Sell
915
-150
-14% -$61.6K ﹤0.01% 2294
2021
Q4 		$466K Sell
1,065
-349
-25% -$175K ﹤0.01% 2472
2021
Q3 		$786K Buy
1,414
+18
+1% +$9.03K ﹤0.01% 2288
2021
Q2 		$716K Sell
1,396
-176
-11% -$112K ﹤0.01% 2455
2021
Q1 		$1.23M Sell
1,572
-1,016
-39% -$696K ﹤0.01% 2159
2020
Q4 		$1.41M Buy
2,588
+814
+46% +$427K ﹤0.01% 1942
2020
Q3 		$812K Buy
1,774
+1,176
+197% +$683K ﹤0.01% 2162
2020
Q2 		$367K Buy
+598
New +$330K ﹤0.01% 2502
2020
Q1 		– Sell
-168
Closed -$97K – 3159
2019
Q4 		$97K Hold
168
– – ﹤0.01% 2896
2019
Q3 		$110K Buy
+168
New +$140K ﹤0.01% 2809
2018
Q1 		– Sell
-173
Closed -$80K – 3018
2017
Q4 		$80K Hold
173
– – ﹤0.01% 2817
2017
Q3 		$85K Sell
173
-712
-80% -$357K ﹤0.01% 2798
2017
Q2 		$490K Sell
885
-501
-36% -$318K ﹤0.01% 2417
2017
Q1 		$918K Buy
1,386
+190
+16% +$101K ﹤0.01% 2142
2016
Q4 		$404K Buy
+1,196
New +$384K ﹤0.01% 2537

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Russell Investments Group's TVRD Position: Q2 2026 in Review

Russell Investments Group increased its Tvardi Therapeutics (TVRD) stake by 85% in Q2 2026, buying an estimated $62.5K and bringing the position to 43,228 shares worth $82.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3504.

Russell Investments Group first reported a position in TVRD in Q4 2016 and has held it in 24 quarters since. The position peaked at $1.41M in Q4 2020. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Russell Investments Group held 43,228 shares of Tvardi Therapeutics worth $82.1K as of Q2 2026.
  • Russell Investments Group bought 19,921 Tvardi Therapeutics shares in Q2 2026, an estimated $62.5K.
  • Tvardi Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3504 holding.
  • Russell Investments Group first reported a position in Tvardi Therapeutics in Q4 2016 and has held it in 24 quarters since.
  • Russell Investments Group's Tvardi Therapeutics position peaked at $1.41M in Q4 2020.
  • 57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.